Home » Newsletters » BioWorld

BioWorld

May 12, 1994

View Archived Issues

STOCKHOLDER PROPOSALS VOTED DOWN AT SCIOS NOVA

ORPHAN DRUG ACT LEGISLATION ON ITS WAY TO SENATE FLOOR

BIOCODE RAISES $4M PRIVATELY

PATENTS ALLOWANCES

EARNINGS REPORTS

OTHER NEWS TO NOTE

CORTECH PLANS SECOND PHASE II SEPSIS TRIAL

FIRST U.S. ANTISENSE ANTI-HIV HUMAN TRIALS START NEXT WEEK

GREENWICH LAYS OFF MOST OF WORK FORCE

CHIRON'S STOCK JUMPS BASED ON MISCUE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...